Hancock Whitney Corp Biogen Inc. Transaction History
Hancock Whitney Corp
- $3.07 Billion
- Q3 2024
A detailed history of Hancock Whitney Corp transactions in Biogen Inc. stock. As of the latest transaction made, Hancock Whitney Corp holds 2,093 shares of BIIB stock, worth $302,250. This represents 0.01% of its overall portfolio holdings.
Number of Shares
2,093
Previous 2,108
0.71%
Holding current value
$302,250
Previous $488,000
17.01%
% of portfolio
0.01%
Previous 0.02%
Shares
28 transactions
Others Institutions Holding BIIB
# of Institutions
1,000Shares Held
130MCall Options Held
1.12MPut Options Held
1.43M-
Vanguard Group Inc Valley Forge, PA16.7MShares$2.41 Billion0.06% of portfolio
-
Primecap Management CO Pasadena, CA16.3MShares$2.36 Billion2.37% of portfolio
-
Black Rock Inc. New York, NY14.5MShares$2.1 Billion0.08% of portfolio
-
State Street Corp Boston, MA7.34MShares$1.06 Billion0.06% of portfolio
-
Jpmorgan Chase & CO New York, NY5.26MShares$759 Million0.08% of portfolio
About BIOGEN INC.
- Ticker BIIB
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 144,000,992
- Market Cap $20.8B
- Description
- Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...